David A. Siegel Reata Pharmaceuticals Inc Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$79.22 - $105.37 $2.22 Million - $2.95 Million	-28,000 Reduced 79.55%	7,200 $734,000
Q1 2023 May 15, 2023	SELL	$30.85 - $93.17 $462,750 - $1.4 Million	-15,000 Reduced 29.88%	35,200 $3.2 Million
Q4 2022 Feb 14, 2023	BUY	$22.15 - $42.11 $558,180 - $1.06 Million	25,200 Added 100.8%	50,200 $1.91 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $485,250 - $912,250	25,000 New	25,000 $628,000
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $485,250 - $912,250	25,000 New	25,000 $628,000
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $5.3 Million - $9.6 Million	-51,989 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$93.53 - $163.34 $851,123 - $1.49 Million	-9,100 Reduced 14.9%	51,989 $5.07 Million
Q2 2020 Aug 14, 2020	BUY	$126.3 - $176.56 $6.92 Million - $9.68 Million	54,800 Added 871.36%	61,089 $9.53 Million
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $780,842 - $1.56 Million	6,289 New	6,289 $908,000
Q2 2019 Aug 14, 2019	SELL	$77.72 - $94.35 $245,284 - $297,768	-3,156 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$51.9 - $101.79 $163,796 - $321,249	3,156 New	3,156 $270,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.